

7. Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. *Acta Med Scand.* 1983;213:27–30.
8. Matsumoto S, Takebayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. *Metabolism.* 2006;55:1645–1652.
9. Zulian E, Sartorato P, Benedini S, et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. *J Endocrinol Invest.* 2005;28:49–53.
10. Kebapcilar L, Taner CE, Kebapcilar AG, et al. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. *Arch Gynecol Obstet.* 2009 (Epub ahead of print).
11. Nakhjavani M, Hamidi S, Esteghamati A, et al. Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. *Br J Clin Pharmacol.* 2009;68:634–637.
12. Studen KB, Sebestjen M, Pfeifer M, et al. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. *Eur J Endocrinol.* 2011;164:389–395.
13. Garca PJ, Miranda ME, Mateos F, et al. Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension. *J Clin Pharmacol.* 1991;31:455–461.
14. Davidson MB, Wong A, Hamrahian AH, et al. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. *Endocr Pract.* 2008;14:985–992.
15. Mehdi UF, ms-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. *J Am Soc Nephrol.* 2009;20:2641–2650.
16. Bombard AS, Muskala P, Bald E, et al. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. *Clin Nephrol.* 2009;72:449–456.
17. Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? *Circ Heart Fail.* 2009;2:370–376.

ERRATUM

Erratum

- *The Journal of Clinical Hypertension (Greenwich).* 2011;13(8):598–604.

Improving Adherence With Amlodipine/Atorvastatin Therapy: IMPACT Study

Saran Oliver, MD; Jennifer Jones, PhD; David Leonard, PhD; Andrew Crabbe, MD; Yana Delkhah, MS3; Shawna Nesbitt, MD, MS

Shawna Nesbitt, MD, MS, was not included in the original published byline. The correct author byline for the article is printed above. The publisher apologizes for the oversight.